Elanco Launches Dedicated Digital Resource Hub To Help Vets Treat Canine Otitis Externa
Elanco Animal Health UK has stepped up its campaign to support vets and veterinary professionals to treat otitis externa (OE) in dogs first time with the launch of its online Ear Health Hub.
The UK division of the international animal health company, which markets Osurnia™ gel treatment for canine OE*, has created the ‘one-stop-shop’ for canine OE information and vet practice support on its MyElanco website.
The Osurnia Ear Health Hub gathers information from experts including veterinary dermatology specialist Sue Paterson, veterinary dermatologist Natalie Barnard, and clinical animal behaviourist Emily Blackwell, all in one place.
It will also host Elanco’s first ever otitis podcast episode, an interview with Sue Paterson, so busy vets and vet nurses can still connect to Elanco’s information hub, even while on the move.
The hub aims to help vets to enhance their skills at each step; CPD resources enable vets to progress their skills in diagnosis and treatment of canine OE, including advise around responsible antibiotic use, expert tips for vets to use in the consulting room today; and dog owner educational materials that veterinary staff can use in practice and online.
It also provides in-depth information, videos and research about first-line treatment Osurnia, the unique gel formulation, which enters the ear as a liquid and spreads along the ear canal as a gel.
Elanco Animal Health UK Marketing Manager, companion animal therapeutics , Rebecca Bryant said: “We know all too well the challenges vets face when treating canine OE and the significant impact the condition has on the quality of life of both the dog and the owner.
“The Osurnia Ear Health Hub is a new disease resource hub on MyElanco, which provides helpful resources for veterinary professionals looking for answers or to enhance their understanding of the disease. We hope that with more easily accessible information, this will help vets to treat OE cases and communicate with their clients.”
Visit the canine ear health hub here
* For the treatment of acute otitis externa and acute exacerbation of recurrent otitis externa associated with Staphylococcus pseudintermedius and Malassezia pachydermatis. Osurnia ear gel for dogs contains terbinafine, florfenicol and betamethasone acetate. PM-IE-19-0078
For additional comment, images, or requests for interviews, please contact:
+44 1273 712146 (direct)
Notes to editors
Osurnia ear gel for dogs contains terbinafine, florfenicol and betamethasone acetate, legal category POM-V in UK, POM in IE. For further information consult the product SPC. Osurnia, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. For further information call Elanco Animal Health on +44(0)1256 353131 or write to: Elanco Animal Health, Lilly House, Priestley Road, Basingstoke, Hampshire RG24 9NL. Use medicines responsibly www.noah.co.uk/responsible www.apha.ie © 2019 Elanco or its affiliates.
Elanco (NYSE: ELAN) is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries. With a 64-year heritage, we rigorously innovate to improve the health of animals and benefit our customers, while fostering an inclusive, cause-driven culture for our 5,700 employees. At Elanco, we’re driven by our vision of food and companionship enriching life – all to advance the health of animals, people and the planet. Learn more at www.elanco.com
More from Elanco
- Elanco launches online social media tutorials in response to vet demand
- Elanco and Onsior launch online an in-practice campaign to help ease the discomfort of canine osteoarthritis
- Onsior (6 mg tablets) receives new indication to treat pain and inflammation in cats with chronic musculoskeletal disease
- Get hands-on and tailor language to engage dog owners in canine osteoarthritis (OA) cases to help take the pain out of consults, encourages RCVS Specialist
- Pain relief is exceptionally important in all cases of otitis externa and should be a priority alongside treatment for clinical resolution, urges leading expert Sue Paterson